Q3 EPS Estimates for Upstream Bio Decreased by William Blair

Key Points

• William Blair has revised its Q3 2025 earnings estimate for Upstream Bio, reducing it from ($0.70) to ($0.78) per share, while the full-year earnings estimate is projected at ($4.30) per share.
• Upstream Bio reported a quarterly EPS of ($0.74), missing analysts' expectations of ($0.61), but achieved a revenue of $0.94 million, surpassing the consensus estimate of $0.32 million.
• Despite the lowered earnings estimates, Wall Street Zen upgraded Upstream Bio from a "sell" to a "hold" rating, with the stock receiving an average rating of "Moderate Buy" and a consensus price target of $56.50.

Upstream Bio, Inc. (NASDAQ:UPB - Free Report) - Stock analysts at William Blair reduced their Q3 2025 earnings per share (EPS) estimates for Upstream Bio in a report issued on Wednesday, August 6th. William Blair analyst M. Phipps now anticipates that the company will post earnings of ($0.78) per share for the quarter, down from their prior forecast of ($0.70). The consensus estimate for Upstream Bio's current full-year earnings is ($4.30) per share. William Blair also issued estimates for Upstream Bio's Q4 2025 earnings at ($0.81) EPS, FY2025 earnings at ($2.84) EPS, Q1 2026 earnings at ($0.82) EPS, Q2 2026 earnings at ($0.69) EPS, Q3 2026 earnings at ($0.62) EPS, FY2026 earnings at ($2.67) EPS, FY2027 earnings at ($2.36) EPS, FY2028 earnings at ($2.47) EPS and FY2029 earnings at ($2.64) EPS.

Separately, Wall Street Zen upgraded Upstream Bio from a "sell" rating to a "hold" rating in a research note on Friday, June 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $56.50.

Upstream Bio Trading Up 4.4%

Shares of UPB stock traded up $0.74 during trading hours on Friday, hitting $17.33. The company had a trading volume of 101,158 shares, compared to its average volume of 350,104. Upstream Bio has a 12 month low of $5.14 and a 12 month high of $29.46. The firm's fifty day moving average is $12.16 and its 200 day moving average is $9.68.

Upstream Bio (NASDAQ:UPB - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.13). Upstream Bio had a negative net margin of 3,836.58% and a negative return on equity of 35.90%. The firm had revenue of $0.94 million for the quarter, compared to the consensus estimate of $0.32 million.

Institutional Investors Weigh In On Upstream Bio

Large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new position in Upstream Bio during the 4th quarter worth $25,000. Legal & General Group Plc acquired a new position in Upstream Bio during the 4th quarter worth $28,000. New York State Common Retirement Fund acquired a new position in Upstream Bio during the 1st quarter worth $29,000. Summit Investment Advisors Inc. acquired a new position in Upstream Bio during the 4th quarter worth $30,000. Finally, CWM LLC lifted its holdings in Upstream Bio by 107.5% during the 2nd quarter. CWM LLC now owns 3,312 shares of the company's stock worth $36,000 after buying an additional 1,716 shares in the last quarter.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.